A biotech that's been misunderstood

Livewire Exclusive

Livewire Markets

Mesoblast was sold off heavily in June following the revelation that Teva had decided to return a number of programs to Mesoblast. Stuart Roberts, Life Sciences Analyst at NDF Research, thinks the market's reaction is all wrong. "I take the view that it's great, because they can take an improved suite of programs that were licensed to Cephalon six years ago, they get them back and they can license them to another partner - I'm hoping, in the not-too-distant future." The stock price has come off heavily from around $11 a few years ago, to around $1 now. However, the company is now looking for FDA approval on their first product, while three others are in Phase 3 trials; "this is a very mature story." In the video below, he examines the risks in the stock and looks at upcoming catalysts for a re-rate.


1 stock mentioned

Livewire Exclusive brings you exclusive content from a wide range of leading fund managers and investment professionals.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.